



**EnLyte**<sup>®</sup>  
Gel Cap

**EnLyte**<sup>®</sup>  
Gummy

**The EnLyte, All-Natural,  
Evidence-Based Story for ADHD  
as Mono or Adjunctive Therapy  
in Preschoolers, Children, Adolescents,  
and Adults**

***ADHD is familial with estimated genetic  
heritability at 80-90% (A significant root cause)***

# The EnLyte Story for ADHD as Mono or Adjunctive Therapy in Preschoolers, Children, Adolescent, and Adults



EnLyte Gummy  
(ages 2-8)



EnLyte Gel Cap  
(No Age Restriction)

CANCELS  
→  
MITIGATES



TO  
→

**Normalize and Balance Biochemical End Points:**  
Neurotransmitters,  
SAM-e, glutathione,  
Taurine, HCY  
DNA, RNA, BH4, NO



## Resulting in Published Clinical Improvements and Remissions for all Ages

**FDA Indication:** Dietary Management of ADHD & Comorbid Depression/Anxiety

“For decades we have treated ADHD and its comorbidities with drugs that temporarily mask symptoms. With EnLyte, we now have the scientific and clinical evidence to address genetic and other root biochemical causes for symptom remissions and prevention effectively and safely over the long haul.”

**B. Andrew Farah** MD, DFAPA

Regional Director Psychiatry, Novant Health, Adjunct Professor of Psychiatry, UNC



# Impactful Polygenic Methylation Genetic Polymorphisms

**MTHFR** SNP, limits Methylfolate production.

**85%**

JCP, 05/16, 330 Patients MDD/MTHFR SNP  
8 Week Monotherapy Study  
EnLyte Group (159) 42% Remission, .93 ES  
Placebo Group (123) 1.8% Remission  
Side Effects = Placebo  
Only MTHFR Study in the Literature

**MTHFD1** SNP, limits Folinic acid production.

**50%**

**DHFR** SNP, limits production of all folates downstream.

**28%**

**SHMT** SNP, limits 5,10 Methylene THF production.

**37%**

**MTR** SNP, limits Methionine Synthase production.

**33%**

**MAO-A** SNP, regulates Neurotransmitter breakdown.

**40%**

**BHMT** SNP, limits Betaine production.

**29%**

**DAO** SNP, Breaks down Histamine improving ADHD symptoms.

**79%**

**HNMT** SNP, Inactivation of Histamine.

**15%**

**COMT** SNP, regulates Dopamine levels in prefrontal cortex.

**25%**

**TCN1/2** SNP, reduces B12 transport intracellularly.

**44%**

**AHCY** SNP, regulates SAH to Homocysteine conversion.

**25%**

**APOE4** SNP, increases brain inflammation.

**20%**

“The broad-spectrum B vitamin coenzymes, mineral cofactors, and phospholipid omega 3 ingredients in EnLyte were specifically designed to empirically manage and mitigate methylation polymorphisms for normal and balanced methylation outcomes, which correlate with proven clinical outcomes in ADHD and Major Depressive Disorder as mono or adjunctive therapy.” — Towny Robinson, Inventor of EnLyte

# Complete Methylation Team

Brain Bio-Active B-Vitamin Coenzymes, Mineral Cofactors, and PS Omega 3s  
Designed to Circumvent All 13 Polygenic Methylation Genetic Polymorphisms

## EnLyte Ingredients

### Reduced Folates

L-Methylfolate Magnesium	7mg
Folinic Acid	3.5mg

### B Vitamins in their Bioactive Coenzyme Form

B12 (Adenosylcobalamin)	50mcg
B6 (Pyridoxal-5-Phosphate)	25mcg
B1 (Thiamine Pyrophosphate)	25mcg
B2 (Flavin Adenine Dinucleotide)	25mcg
B3 (Nicotinamide Adenine Dinucleotide)	25mcg
Bioperine (B Vitamin Bioenhancer)	500mcg
Betaine (Trimethyl Glycine)	1mg

### Minerals in their Bioactive Cofactor Form

Magnesium Ascorbate	24mg
Magnesium L-Threonate	1mg
Zinc Ascorbate	1mg
Ferrous Glycine Cysteinate	1.5mg

### Phospholipid Form—Brain Ready

PS-Omega-3 (Phosphatidylserine, EPA, DHA)	23.3mg
---	--------

### Absorption Enhancer

Sodium Citrate	6mg
----------------	-----

### Energizer

CoQ10	500mcg
-------	--------

## EnLyte Gummy Ingredients

L-Methylfolate (Magnesium):	1.7 mg
B12 (Methylcobalamin):	16.7 mcg
B6 (Pyridoxine Hydrochloride):	16.7 mcg
B1 (Thiamine HCl):	8.3 mcg
B2 (Riboflavin):	8.3 mcg
B3 (NAD):	8.3 mcg
DHA/EPA Omega Ahiflower Algal Oil Blend:	2.7 mg
Phospholipid (Phosphatidylserine):	25 mg
Magnesium Citrate:	16.7 mg
Zinc Citrate:	6.7 mg


### Q. What is the difference in a vitamin and a vitamin coenzyme?

A. Coenzymes are in their final metabolized forms, making them ready to be the catalyst fuel for methylation production of biochemical end points.

# Methylation Chart

EnLyte/EnLyte Gummy provides all the downstream bio-active coenzymes, cofactors, and omegas needed to normalize and balance biochemical endpoints, which correlates into clinical remissions in depression/ADHD clinical trials.

**EnLyte, EnLyte Gummy Coenzyme/Cofactor Product Ingredients Maroon,**  
**Biochemical End Points Green, Enzymes Purple, SNP Incidence Blue**



\*Kennedy, David O., B Vitamins and the Brain: Mechanisms, Dose and Efficacy - A Review, Figure 2. The interlinked folate and methionine cycles.

# A Nutrigenomic Coenzyme/Cofactor Monotherapy for Pediatric ADHD Ages 2-12

An Open Label Preliminary Trial and Abbreviated Case Series.  
Jaimee Arroyo FNP-BC



## Case 1

3-year-old male

**Baseline symptoms:** Inattentive to instructions; anger with routine tasks (dressing, brushing teeth); could not sit still unless highly engaged

**Conners: 55 → 27**

**Genetics:** MTHFR A1298C (hetero); very slow MAO; very fast COMT

**Adherence/Duration:** 75% compliance (EnLyte PD Gummy), 90 days

**Outcome:** Following preschool directions; outbursts resolved

## Case 2

10-year-old male

**Baseline symptoms:** Performs below grade level; poor concentration leads to frustration; anxiety with incomplete work and task switching; difficulty stopping tasks; low self-esteem (“I have no friends”)

**Conners: 46 → 21**

**Genetics:** MTHFR C677T (hetero); slow COMT; very fast MAO

**Adherence/Duration:** 75% compliance (ENL Gel Cap), 90 days

**Outcome:** Improved focus at home/school; gets less emotional; improved friendships; antidepressant no longer needed/considered

# Cont. A Nutrigenomic Coenzyme/Cofactor Monotherapy for Pediatric ADHD Ages 2-12

An Open Label Preliminary Trial and Abbreviated Case Series.  
Jaimee Arroyo FNP-BC



## Case 3

11-year-old female

**Baseline symptoms:** Poor memory for instructions; “brain fog” in class; emotionally over-reactive; obsessed over internal timelines with “meltdowns” when expectations disrupted; rushed work with near-complete assignments left unfinished; high anxiety (OCD therapy considered)

**Conners: 40 → 16**

**Genetics:** MTHFR C677T/A1298C (compound hetero); slow COMT; severely reduced DAO

**Adherence/Duration:** 100% compliant (EnLyte PD Gummy), 90 days

**Outcome:** Requires less time and support to cope with routine anxiety triggers; decreased need for extended conversations and interventions; improved self-control with slower, more deliberate responses; increased focus and independence with chores and medial tasks without prompting.

**Additional outcome:** Y-BOCS 41 → 20

## RESULTS:

All 38 study completers responded well to EnLyte Gummy or gel caps, with the mean reduction in the Conners' Parent Rating Scale from 54.7 (Moderate ADHD) to 29.6 (Wellness or remission) after 90 days of therapy.

# Addressing the ADHD Symptom Triad with EnLyte Adjunctively:

## Focus, Emotional Dysregulation, & Psychiatric Comorbidities

NIH/CDC states that 80% of ADHD children have at least one psychiatric comorbidity



### Case 1

**7-year-old female (ADHD; stimulant + EnLyte)**

#### **Baseline/treatment history:**

Improved focus/grades on methylphenidate 27 mg, but worsened mood symptoms

**Presenting symptoms:** Poor frustration tolerance; anger outbursts → remorse, dysphoria, guilty ruminations

**Adjustment:** Reduced methylphenidate to 18 mg (mood returned to baseline but still problematic)

**EnLyte outcome:** Once-daily EnLyte resolved mood/emotional issues within 6 weeks (only minor flare-ups)

**Long-term:** Continued combination therapy for **>2 years**



### Case 2

**10-year-old male (ADHD + depressive symptoms; stimulant + EnLyte)**

#### **Current meds (baseline):**

Methylphenidate 20 mg AM + 5 mg after school

#### **Presenting symptoms:**

Moodiness, irritability, feeling down most of the time

#### **Prior antidepressant trials:**

Fluoxetine 10 mg/day and escitalopram 20 mg/day (parents reported worsening)

**EnLyte outcome:** Added once daily → MDD remission by week 8. **MADRS:** 21 → 6

**Long-term :** Symptom resolution sustained over 1 year at present

# Beyond its Proven Therapeutic Effect, EnLyte Fully Nourishes the Brain

## NUTRITIONAL DEFICIENCIES PLAGUE 90% OF ADHD KIDS



Stimulants Reduce Appetite  
Affecting Nutrition



Drugs Impair Digestion,  
Absorption, and Storage



SNRIs/SSRIs Increase  
Cravings that Alters Nutrition



Environmental Contaminants  
Deplete Nutrition



Stimulants Increase Excretion  
of Nutrients



Genetic Polymorphisms Cause  
Coenzyme Deficiencies

### PSYCHIATRIC MEDS DEplete


Magnesium  
Iron  
Folates  
Omega 3s  
B1  
B12  
B6  
B2  
B3  
Zinc  
CoQ10

### ENLYTE SUPPLEMENTS

+ Magnesium 3 ways  
+ Iron Mildly with Chelation  
+ Methylfolate, Folinic Acid  
+ Brain Omega same as Vayarin  
+ B1 Coenzyme  
+ B12 Coenzyme  
+ B6 Coenzyme  
+ B2 Coenzyme  
+ B3 Coenzyme  
+ Zinc Ascorbate  
+ CoQ10



EnLyte can double as the  
best vitamin for general  
health benefits: Improving  
compliance and saving  
money



# HOW TO PRESCRIBE

Submit Our Electronic Form

## Step 1

Visit

[www.enlyterx.com](http://www.enlyterx.com)

Fill out info and click “submit”  
EnLyte will be available in your EMR, but the most cost-effective way to prescribe is by using the "Prescribe Now" button. This ensures your patients receive 2 bottles at \$29.95 each, and the lowest price available moving forward. EnLyte Gummy is always \$99 for 90 Gummies.

## Step 2

### Inform Your Patient

Let your patient know that a friendly customer care representative will contact them shortly to get started on EnLyte for just \$1 a day for the first 60 days. EnLyte Gummy is always \$99 for 90 gummies.

### We Take Care of The Rest

A representative will contact your patient to arrange their order, which will typically be shipped the same day.

Our Medical Food Distributor will handle all refills to ensure uninterrupted care.